Resource Center

Apr 30, 2015
  |  Press Release

Simulations Plus Releases GastroPlus Version 9.0

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released the long-awaited Version 9.0 of its flagship GastroPlus™ simulation software.

Dr. Michael Bolger, chief scientist of Simulations Plus, said: “We’re very pleased to announce the release of GastroPlus Version 9.0. This is the largest single upgrade we’ve made to the program to date, and the level of science and technology adds valuable new functionalities that we believe will provide the most advanced decision-making tool for preclinical and early clinical trial simulation and modeling analysis available today. Several of the significant enhancements include:

  • ability to simulate the absorption and distribution of biologics (antibodies and proteins)
  • ability to simulate dosing to the skin, including patches, creams, ointments, and subcutaneous injections
  • tighter integration with our ADMET Predictor™ software to increase the utility of the program in early drug discovery.”

Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added: “GastroPlus is all about integrating the best science into user-friendly software to enable pharmaceutical researchers and regulators to perform sophisticated analyses of complex drug behaviors in humans and laboratory animals. Already the most widely used program in the world for physiologically based pharmacokinetics (PBPK), the addition of these new capabilities is expected to expand the user base earlier into the research & development process within the pharmaceutical industry, while also helping us further penetrate the biopharmaceuticals, food, cosmetics, and general toxicology markets.”

Dr. Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen Corporation, said, “The release of GastroPlus 9.0 is the culmination of many months of hard work by Dr. Viera Lukacova and her Simulation Technologies team, supported by a large number of other scientists and engineers within Simulations Plus. Some of our customers have been using portions of the new features for over a year and have provided valuable feedback to improve the code. We’re excited about the possibilities that this new release brings and how it can further increase the efficiency of model-based drug development.”

Contact Us About This Press Release